Skip to content
OpenCapital
Get started

Pfizer PFE Paxlovid — Remaining performance obligation

Other product segments

Comirnaty
$2.1B-30.0%

Similar metrics at other companies

FuelCell Energy logo
FCELProduct — Revenue Remaining Performance Obligation
$36.1M-63.2%
Abbott logo
ABTPharmaceuticals — Remaining performance obligations
$258M—
Cisco Systems, Inc. logo
CSCOProduct — Remaining performance obligation
$22.06B+6.3%
Schneider National logo
SNDRLogistics Management — Remaining Performance Obligation
$17.5M-28.3%
Wyndham Hotels & Resorts, Inc. logo
WHOther — Remaining performance obligation
$18M-45.5%
ANI Pharmaceuticals logo
ANIPSales of contract manufactured products — Remaining performance obligations
$3.2M—

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$134.91B-1.0%
Enterprise value$197.57B+0.7%
P/E11.1×—
P/S2.1×-0.1×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's paxlovid — remaining performance obligation.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's paxlovid — remaining performance obligation?
Pfizer (PFE) reported paxlovid — remaining performance obligation of $948M in Q1 2026.
How has Pfizer's paxlovid — remaining performance obligation changed year-over-year?
Pfizer's paxlovid — remaining performance obligation decreased by 5.2% year-over-year, from $1B to $948M.
What does paxlovid — remaining performance obligation mean?
This metric represents the total transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period for the specific pharmaceutical product segment. It reflects the value of contracted revenue that the company expects to recognize in future periods as it fulfills its obligations to customers. This provides visibility into the future revenue backlog associated with specific therapeutic products or vaccine contracts.